ACE-inhibitors are considered to be potentially beneficial, especially for RHD, not only in interfering with the RAA system but also for attenuating myocardial fibrosis by inhibiting TGF-β signaling (42, 75). The gene discussed is TGFB1; the disease is rheumatic heart disease.